Stem cells, exosomes, gene therapy, peptides, hyperbaric oxygen, and epigenetic reprogramming
348 articles
Early data suggests the latest KRAS-targeting drugs outperform their predecessors in lung cancer treatment, marking a potential breakthrough.
Scientists harness natural bacterial mutation systems to engineer proteins at unprecedented speed, opening doors for drug and therapy development.
A new nanopore-based approach aims to sequence peptides by reversing the translation process, potentially transforming proteomics.
Activating three Yamanaka factors — OCT4, SOX2, and KLF4 — appears to reverse epigenetic aging in human eye cells, marking a milestone in rejuvenation medicine.
A landmark Cell study reveals p53 actively enables chemical reprogramming to pluripotency, overturning assumptions and boosting regenerative medicine safety.
The EV therapy pipeline is expanding rapidly, but standardization and clinical proof remain elusive challenges for this emerging field.
New comprehensive review questions effectiveness of amyloid-targeting Alzheimer's drugs, igniting debate over treatment approach.
New study suggests Lilly's tirzepatide leads to more lean muscle loss compared to Novo's semaglutide, despite superior weight loss results.
Breakthrough therapy targeting hypoxic-ischemic encephalopathy in newborns receives significant funding, potentially becoming first HIE drug.
New technique enables researchers to study how proteins change shape when exposed to light, advancing structural biology research.
Researchers developed a breakthrough technique to cryopreserve cardiac endothelial cells with 95% viability for regenerative medicine.
Interrupted cooling protocols boost cell viability in cryopreservation by optimizing freeze-thaw timing and temperature control.
